Pharm

Omalizumab

search

Omalizumab, rhuMAb-E25

  • Indications (all required)
  1. Refractory moderate to Severe Persistent Asthma
  2. Positive Allergy Testing for perennial inhaled allergen
  3. Patients must be age 12 years or over
  • Mechanism
  1. Recombinant humanized Monoclonal Antibody (rhu-MAB)
  2. Blocks IgE binding to mast cells and Basophils
    1. Prevents release of Allergic Reaction mediators
  • Adverse effects
  1. Serious and life-threatening
    1. May predispose to malignancy
    2. Anaphylaxis
      1. Requires administration in clinical setting
      2. Reaction may occur within 2 hours of injection
  2. Other reactions
    1. Injection site reaction
    2. Upper Respiratory Infections (including Sinusitis, Pharyngitis)
    3. Headache
  • Efficacy
  1. Appears to be very effective in first year of use
  • Cost
  1. Dose dependent
  2. Varies from $500 to over $3000 for one month supply
  • Dosing
  1. Dose determined by serum IgE level
  2. Usually 150 to 375 mg SQ every 2-4 weeks
  3. Must be given in clinical setting with observation